Overview of PhIP-Seq.
Bacteriophage Immunoprecipitation Sequencing (PhIP-Seq) is a powerful new method of multiplexed analysis that combines DNA high-throughput sequencing with next-generation proteomics. PhIP-Seq allows researchers to determine what antibodies were created by an individual’s unique history of immune exposures. PhIP-Seq is the highest-coverage antigen-specific assay yet developed, able to detect antibodies versus virtually any antigen via overlapping long peptides.
PhIP-Seq was developed at Harvard University in 2011. This work created a synthetic representation of the complete human proteome as a T7 bacteriophage display library. They built upon this work in 2015 by creating a synthetic representation of the complete human virome: the universe of known infectious viruses.
Since then, PhIP-Seq has been used to perform revolutionary immune profiling on people suffering from measles, multiple sclerosis, diabetes, rheumatoid arthritis, and more. CDI Labs was the first company to commercialize PhIP-Seq technology.